Want to see SCNI full AI Analyst Report?
SCNI Stock Chart & Stats
$0.78
-$0.11(-3.01%)
At close: 4:00 PM EST
$0.78
-$0.11(-3.01%)
Day’s Range― - ―
52-Week Range$0.24 - $3.48
Previous CloseN/A
Volume8.73K
Average Volume (3M)101.31K
Market Cap
$912.16K
Enterprise Value$825.28K
Total Cash (Recent Filing)$3.11M
Total Debt (Recent Filing)$3.50M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3837.20
Shares Outstanding3,959,792
10 Day Avg. Volume127,573
30 Day Avg. Volume101,310
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.21
Price to Sales (P/S)1.27
P/FCF Ratio-0.27
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue0.58
Enterprise Value/Gross Profit-0.26
Enterprise Value/Ebitda-0.11
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
CDMO Expansion / Manufacturing CapacityThe Recipharm Israel acquisition creates a second GMP-capable site and broadens biologics, sterile injectables and API capabilities. Structurally this diversifies revenue toward CDMO services, supports multi-site operations, and builds a foundation for steadier contract revenue versus single-product biopharma risk.
Improved Capitalization / Manageable LeverageDebt-to-equity near 0.28–0.30 and a materially improved equity base versus prior years reduces solvency pressure and increases financial flexibility. This stronger capitalization improves ability to fund CDMO integration, secure supplier terms, and raise project financing without immediate distress-driven constraints.
Early Revenue Traction And CommercializationRevenue growth from near-zero to ~$1.4M TTM shows tangible commercialization progress and meaningful CDMO/customer contract contribution. Durable revenue momentum, if sustained and scaled with the new manufacturing capability, can underpin operational breakeven and reduce dependence on capital markets over the medium term.
Bears Say
Persistent Negative Cash FlowConsistent negative operating cash flow (TTM ~ -$6.4M) and negative free cash flow indicate ongoing cash burn. Absent material revenue scale-up or structural cost cutting, the company will remain dependent on external financing, increasing dilution risk and constraining long-term investment in R&D and CDMO capacity expansion.
Negative Gross Profit And Large Operating LossesNegative gross profit and very large operating losses versus modest revenue reflect a cost structure built for development rather than commercial margins. This structural lack of profitability means scaling revenue alone may not suffice without addressing COGS, SG&A and operating efficiencies to achieve sustainable margins.
Acquisition Integration And Going-Concern RiskPro forma audited results for the acquired unit revealed losses, working capital shortfalls and a significant equity deficit with an auditor going-concern emphasis. This raises lasting integration and liability risks: the subsidiary may require ongoing support, additional capital, or restructuring, which can offset balance-sheet gains and strain resources.
Scinai Immunotherapeutics News
SCNI FAQ
What was Scinai Immunotherapeutics’s price range in the past 12 months?
Scinai Immunotherapeutics lowest stock price was $0.24 and its highest was $3.48 in the past 12 months.
What is Scinai Immunotherapeutics’s market cap?
Scinai Immunotherapeutics’s market cap is $912.16K.
When is Scinai Immunotherapeutics’s upcoming earnings report date?
Scinai Immunotherapeutics’s upcoming earnings report date is Aug 20, 2026 which is in 40 days.
How were Scinai Immunotherapeutics’s earnings last quarter?
Scinai Immunotherapeutics released its earnings results on Jun 10, 2026. The company reported $0 earnings per share for the quarter, the consensus estimate of N/A by $0.
Is Scinai Immunotherapeutics overvalued?
According to Wall Street analysts Scinai Immunotherapeutics’s price is currently Overvalued.
Does Scinai Immunotherapeutics pay dividends?
Scinai Immunotherapeutics does not currently pay dividends.
What is Scinai Immunotherapeutics’s EPS estimate?
Scinai Immunotherapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scinai Immunotherapeutics have?
Scinai Immunotherapeutics has 3,959,792 shares outstanding.
What happened to Scinai Immunotherapeutics’s price movement after its last earnings report?
Scinai Immunotherapeutics reported an EPS of $0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -7.627%.
Which hedge fund is a major shareholder of Scinai Immunotherapeutics?
Currently, no hedge funds are holding shares in SCNI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licensing and collaboration agreement with the Max Planck Society and the University Medical Center Göttingen. This partnership is focused on advancing and commercializing a nanosized antibody (NanoAb) specifically for COVID-19, in addition to pursuing NanoAb applications for various other disease indications. Established in 2003, the company was formerly known as BiondVax Pharmaceuticals Ltd. before rebranding to Scinai Immunotherapeutics Ltd. in September 2023. Its corporate headquarters are situated in Jerusalem, Israel.
Technical Analysis
Ownership Overview
― Insiders
―
Mutual Funds
0.37% Other Institutional Investors
99.63% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---